Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-15

FDA Approved: BRIXADI — Supplemental Application (Braeburn Inc.)

View source ↗

Summary

The FDA approved Braeburn Inc.'s supplemental application for BRIXADI (buprenorphine), indicating an update to the product's labeling under a supplemental appro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRIXADI (Buprenorphine)

Snippet

SUPPL AP for BRIXADI (BUPRENORPHINE)